For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $4.91 in the prior trading day, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $4.98, up 1.43%. In other words, the price has increased by $1.43 from its previous closing price. On the day, 29.67 million shares were traded. RXRX stock price reached its highest trading level at $5.265 during the session, while it also had its lowest trading level at $4.92.
Ratios:
Our goal is to gain a better understanding of RXRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.58 and its Current Ratio is at 3.58. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.07.
On May 22, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $8. On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.Needham initiated its Buy rating on March 16, 2023, with a $17 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 10 ’25 when Gibson Christopher sold 100,000 shares for $4.71 per share. The transaction valued at 471,000 led to the insider holds 974,229 shares of the business.
Gibson Christopher bought 100,000 shares of RXRX for $471,000 on Sep 10 ’25. On Aug 26 ’25, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 100,000 shares for $4.84 each. As a result, the insider received 484,000 and left with 954,229 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2174011648 and an Enterprise Value of 1727588096. For the stock, the TTM Price-to-Sale (P/S) ratio is 33.51 while its Price-to-Book (P/B) ratio in mrq is 2.35. Its current Enterprise Value per Revenue stands at 26.745 whereas that against EBITDA is -2.946.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.91, which has changed by -0.2719298 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is -5.96%, while the 200-Day Moving Average is calculated to be -16.37%.
Shares Statistics:
The stock has traded on average 24.42M shares per day over the past 3-months and 25704530 shares per day over the last 10 days, according to various share statistics. A total of 425.48M shares are outstanding, with a floating share count of 332.98M. Insiders hold about 23.39% of the company’s shares, while institutions hold 53.78% stake in the company. Shares short for RXRX as of 1756425600 were 124079106 with a Short Ratio of 5.08, compared to 1753920000 on 117535748. Therefore, it implies a Short% of Shares Outstanding of 124079106 and a Short% of Float of 30.5.
Earnings Estimates
The dynamic stock of Recursion Pharmaceuticals Inc (RXRX) is currently attracting attention from 6.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.26 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$1.29 and -$1.8 for the fiscal current year, implying an average EPS of -$1.58. EPS for the following year is -$1.28, with 9.0 analysts recommending between -$0.81 and -$1.6.
Revenue Estimates
5 analysts predict $19.36M in revenue for the current quarter. It ranges from a high estimate of $23.9M to a low estimate of $16M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $26.08MFor the next quarter, 5 analysts are estimating revenue of $17.7M. There is a high estimate of $20.6M for the next quarter, whereas the lowest estimate is $16M.
A total of 9 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $95.5M, while the lowest revenue estimate was $48.35M, resulting in an average revenue estimate of $69.68M. In the same quarter a year ago, actual revenue was $58.84MBased on 9 analysts’ estimates, the company’s revenue will be $97.31M in the next fiscal year. The high estimate is $208.4M and the low estimate is $45M.
